RecruitingNCT07226219
Methylphenidate for attention and thinking difficulties in children with sickle cell disease
About this title
Read the official source — NCT07226219Medication studyAges 8–17United StatesADHD
Understand this study
Who could participate?
Listed age limits: 8 years to 17 years.
What will I do during this study?
Your child takes extended-release methylphenidate once daily for four weeks. The study assesses thinking and attention before treatment and again after the treatment period.
- Listed locations
- MemphisSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Participation duration
- Daily medication is taken for 4 weeks.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 25, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 72
- Sponsor
- St. Jude Children's Research Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 8 Years to 17 Years
- Official registry ID
- NCT07226219
- Official title
Show the full official title
Pilot Trial of Stimulant Treatment to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Memphis
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is St. Jude Children's Research Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Extended-Release Methylphenidate.
Who can participate?
Listed age limits: 8 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
